Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Date:8/7/2008

cs. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing. The results of early preclinical studies or clinical trials may not be predictive of future results, and the Company cannot provide any assurances that any of its compounds or development candidates will have favorable results in preclinical studies or future clinical trials. In addition, results may be affected by the failure to enter into new collaborations on any of its research and development programs in the event that the merger transaction is not consummated, competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, the scope and validity of patent protection for its products, and its ability to obtain additional funding to support its operations. For a discussion of these and other factors, please refer to the risk factors described in the Company's annual report on Form 10-K for the year ended December 31, 2007 and the Company's most recent quarterly report on Form 10-Q as well as subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and SGX undertakes no obligation to revise or update this press release to reflect events or circumstances af
'/>"/>
SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
9. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
10. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
11. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4ld5nw/mature_biotech ) ... Outlook 2015: New Therapy Ventures Pave the Way for ... All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen ... given a positive return and hence increased the interest ... select therapy/niche indication where the high treatment cost justifies ...
(Date:3/5/2015)... The next implants made from the PEEK-OPTIMA® ... (European) approval. The CE mark is necessary for distributing ... the European Union. Following the Class IIb approval route, ... supplied by the Turkey-based company Osimplant for the treatment ... Expandable Bladed HA PEEK Cage line of spinal implants, ...
(Date:3/4/2015)... 4, 2015 In an article published and ... for Health Security review the clinical aspects of diseases ... as bioweapons. The article, "Clinical Management of Potential Bioterrorism-Related ... website of the New England Journal of Medicine ... Toner , and Tom Inglesby—review the clinical management of ...
(Date:3/4/2015)... 2015 USDM Life Sciences , ... sciences industry, hired David Blewitt as Vice ... Compliance Services and Solutions at USDM Life Sciences , ... while maintaining compliance with government regulations worldwide. , ... accomplished life sciences regulatory and IS compliance professional with ...
Breaking Biology Technology:Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3Latest Clinical Information On Bioterrorism Threats 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3
... DIEGO, April 14 XIFIN Inc., the ... diagnostic laboratories, announced today that XIFIN,s CEO ... at the Executive War College Conference in ... attendance will be senior executives, laboratory administrators ...
... to begin after markets close at 2:00 p.m. PT (5:00 ... MASI ), the inventor of Pulse CO-Oximetry and Measure-Through ... first quarter 2009 financial results for the period ended April ... 2009.A conference call to review the results will begin at ...
... N.C., April 14 Pharmaceutical Institute (PI), the ... pharmaceutical and biotech industry, today announced the release ... Markets Excellence(TM) . The series was developed ... leaders from 17 large and midsize pharmaceutical and ...
Cached Biology Technology:XIFIN Inc. CEO to Speak at Executive War College Conference 2XIFIN Inc. CEO to Speak at Executive War College Conference 3Masimo to Report First Quarter 2009 Financial Results on May 5, 2009 2Masimo to Report First Quarter 2009 Financial Results on May 5, 2009 3Pharmaceutical Institute Launches New Training Series Focused on Managed Markets Excellence 2Pharmaceutical Institute Launches New Training Series Focused on Managed Markets Excellence 3
(Date:3/2/2015)... 2015   Neurotechnology , a provider of high-precision ... SentiGaze Software Development Kit (SDK). The SentiGaze algorithm ... off-the-shelf webcams to track eye movements and generate heatmaps ... Heatmaps can be used for applications such as analysis ... The SDK can also be used to develop interfaces ...
(Date:2/24/2015)... YORK , Feb. 24, 2015 This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided for the ... provided for these markets. Market data and analytics are derived ...
(Date:2/24/2015)... DUBLIN , Feb. 24, 2015 Research ... announced the addition of the "Global 2D ... offering. The analysts forecast the ... a CAGR of 32.12% over the period 2014-2019 ... devices in non-traditional sectors is one of the ...
Breaking Biology News(10 mins):Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2
... Researchers working with rats have zeroed in on the ... behavior seen in users of cocaine as well as ... in such disorders as schizophrenia, depression, and post-traumatic stress ... A. Grace of the University of Pittsburgh described their ...
... rises during pregnancy, according to a study of women ... Johns Hopkins Bloomberg School of Public Health. The increased ... for behavior and other factors that contribute to HIV ... 30, 2005, edition of The Lancet, suggest that the ...
... puzzle in Alzheimer's disease (AD) research is why mice ... in humans show little pathology of the disease. Specifically, ... amyloid precursor protein (APP). It is this protein that, ... peptide that clusters into the amyloid plaque that clogs ...
Cached Biology News:New clue to cocaine addicts' quirky behavior 2Pregnant women at higher risk for HIV, Uganda study finds 2Pinpointing a culprit molecule in Alzheimer's disease 2
... 1 outflow Single-cell and patch delivery ... solution change Very small dead volume , ... 360, 250 and 100 micron delivery tips ... micromanipulator Available in 4, 8, and 16 ...
... are ideal for storage and transport of ... racks withstand extreme temperatures, making them an ... also be autoclaved for use in sterile ... accommodates 0.5ml microcentrifuge tubes, the other 1.5ml ...
... This kit consists of universal lysis ... control primers for 100 25 l volume ... types of Gram negative or positive rod ... Klebsiella Pneumoniae, Bacillus Cereus, Staphylococcus Aureus, Streptococcus ...
... optimized for serum-free growth of Ready-Plaque Sf9 ... medium, Sf9 cultures routinely reach densities greater ... above 95%. This medium is also recommended ... staining of pBACgus recombinants develops faster than ...
Biology Products: